News BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
27.05 ^USD	-0.26%		-3.43%	-32.99%

Jun. 04	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	MT
Jun. 04	BridgeBio Pharma Phase 2 Trial of Infigratinib Shows 'Continued Well-Tolerated Safety Profile'; Starts Phase 3 Trial Enrollment	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO	Jun. 07	PR
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference	Jun. 06	GL
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Jun. 05	BU
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Jun. 04	MT
BridgeBio Pharma Phase 2 Trial of Infigratinib Shows 'Continued Well-Tolerated Safety Profile'; Starts Phase 3 Trial Enrollment	Jun. 04	MT
Transcript : BridgeBio Pharma, Inc. - Special Call	Jun. 04
BridgeBio Pharma : BBIO – Infigratinib – PROPEL 2 Data Update and ACCEL Program Initiation	Jun. 04	PU
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia	Jun. 04	GL
BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia	Jun. 04	CI
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024	Jun. 03	GL
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ENDO 2024 Characteristics of Adults with ADH1 enrolled in CLARIFY	Jun. 03	PU
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study	May. 30	AQ
Transcript : BridgeBio Pharma, Inc. - Special Call	May. 29
BridgeBio Pharma : BBIO Acoramidis (AG10) TTR ISA 2024 Featured research in the ATTR CM landscape	May. 29	PU
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	May. 29	GL
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis achieves early reduction in cardiovascular death or hospitalization in transthyretin amyloid cardiomyopathy (ATTR-CM)	May. 29	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM	May. 29	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients	May. 29	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy	May. 29	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Rationale & design of ACT-EARLY	May. 29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Summary

Filters